Insider Transactions in Q4 2021 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
52,950
+14.62%
|
-
|
|
Dec 16
2021
|
John Northcott SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,800
+13.98%
|
-
|
|
Dec 16
2021
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
126,050
+17.33%
|
-
|
|
Dec 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,200
+11.22%
|
-
|
|
Dec 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,800
+23.26%
|
-
|
|
Dec 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,950
+15.67%
|
-
|
|
Nov 18
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
3,000
-1.16%
|
$36,000
$12.69 P/Share
|
|
Nov 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
21,149
-7.53%
|
$274,937
$13.16 P/Share
|
|
Nov 16
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,061
-3.02%
|
$78,793
$13.16 P/Share
|
|
Nov 16
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
42,773
-8.25%
|
$556,049
$13.16 P/Share
|
|
Nov 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,741
-4.41%
|
$87,633
$13.16 P/Share
|
|
Nov 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,564
-7.06%
|
$85,332
$13.16 P/Share
|
|
Nov 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
20,869
-8.25%
|
$271,297
$13.16 P/Share
|
|
Nov 15
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,150
+12.51%
|
-
|
|
Nov 15
2021
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,100
+15.37%
|
-
|
|
Nov 15
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,900
+8.89%
|
-
|
|
Nov 15
2021
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+17.77%
|
-
|
|
Nov 15
2021
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,150
+13.7%
|
-
|
|
Nov 11
2021
|
Diana Brainard Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,360
+50.0%
|
-
|
|
Nov 09
2021
|
R Scott Greer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+4.09%
|
$150,000
$12.8 P/Share
|